Carvedilol
- Generic Name
- Carvedilol
- Brand Names
- Coreg
- Drug Type
- Small Molecule
- Chemical Formula
- C24H26N2O4
- CAS Number
- 72956-09-3
- Unique Ingredient Identifier
- 0K47UL67F2
- Background
Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunction, and hypertension. The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension.
Carvedilol was granted FDA approval on 14 September 1995.
- Indication
Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.
- Associated Conditions
- Atrial Fibrillation, Chronic Stable Angina Pectoris, Hypertension, LVEF ≤40% Left ventricular dysfunction, NYHA Class I or II heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV)
Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- State University of New York at Buffalo
- Target Recruit Count
- 30
- Registration Number
- NCT00657241
- Locations
- 🇺🇸
Erie County Medical Center, Buffalo, New York, United States
Fed Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 50
- Registration Number
- NCT00648622
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Fasting Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 50
- Registration Number
- NCT00650416
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Comparison of Blood Pressure Medications on Metabolism
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 22
- Registration Number
- NCT00642434
- Locations
- 🇺🇸
UNMHSC, Albuquerque, New Mexico, United States
Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2016-12-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 348
- Registration Number
- NCT00624065
- Locations
- 🇺🇸
GSK Investigational Site, Beloit, Wisconsin, United States
The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy
- First Posted Date
- 2008-02-05
- Last Posted Date
- 2008-02-05
- Lead Sponsor
- Suzuka Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00606775
- Locations
- 🇯🇵
Suzuka Hospial, Suzuka, Mie, Japan
Cocaine Withdrawal and Pharmacotherapy Response
- Conditions
- Opiate DependenceCocaine Dependence
- Interventions
- First Posted Date
- 2007-12-04
- Last Posted Date
- 2020-04-02
- Lead Sponsor
- Yale University
- Target Recruit Count
- 106
- Registration Number
- NCT00566969
- Locations
- 🇺🇸
Veterans Hospital, West Haven, Connecticut, United States
Study to Demonstrate the Bioequivalence of the Fixed Dose Combination of COREG CR™ and Lisinopril to Its Components
- Conditions
- Hypertension
- First Posted Date
- 2007-11-12
- Last Posted Date
- 2010-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 50
- Registration Number
- NCT00556920
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
Study to Examine the Effect of Food on the Pharmacokinetics of the Fixed Dose Combination of COREG CR and Lisinopril.
- Conditions
- Hypertension
- First Posted Date
- 2007-11-12
- Last Posted Date
- 2010-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT00557128
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease
- Conditions
- Pre-hypertension
- Interventions
- Drug: placebo and placebo
- First Posted Date
- 2007-11-06
- Last Posted Date
- 2018-04-24
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 101
- Registration Number
- NCT00553969
- Locations
- 🇺🇸
University of Minnesota, Variety Club Research Center 102, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.